A 4-month-old white female presented with a 2-month history of a diffuse petechial rash, intermittent fever, and worsening anemia and thrombocytopenia. She had a life-long history of spitting-up attributed to gastroesophageal reflux. However, over the preceding 2 weeks she developed nonbloody vomiting and a decrease in oral intake. During this time, she also developed diarrhea, having 5 bowel movements per day that contained mucus but no visible blood. She was treated sequentially with an H2-receptor antagonist and a proton-pump inhibitor without improvement. The patient was admitted to the hospital for further evaluation and treatment with a presumptive diagnosis of Langerhans cell histiocytosis (LCH). Examination revealed weight at the 10th percentile, length at the 25th percentile, head circumference at the 50th percentile, and weight-to-length ratio at the 25th percentile. There was no sclera icterus. Heart and lung examinations were normal. The abdomen was soft and nontender with hepatomegaly; the liver was palpable below the right costal margin and extended across the midline. No spleen was palpable. No lymphadenopathy was noted. Skin examination revealed a diffuse papular and petechial rash. Edema was present in the face, hands, and feet. The stool was positive for fecal occult blood.Pertinent laboratory studies included white blood cell count (8210/mm 3 ), hemoglobin (9.7 g/dL), hematocrit (30.5%), platelet count (49 000/mm 3 ), total protein (3.3 g/dL), and albumin (1.9 g/dL). A liver panel, serum electrolytes, and glucose were normal. Routine urinalysis was negative for proteinuria. Fecal α-1-antitrypsin level was elevated at 340 mg/dL (normal <55 mg/dL).Imaging studies did not reveal any bone lesions. A bone marrow aspirate and biopsy were performed and found to be normal. A punch biopsy of a skin lesion obtained at the time of the bone marrow procedure revealed LCH. When there was no improvement in gastrointestinal symptoms an upper endoscopy and colonoscopy were performed. Esophagogastroduodenoscopy (EGD) showed abnormal duodenal mucosa with edema, erythema, and a granular appearance with an overlying exudate (Figure 1). Colonoscopy revealed loss of vascular marking, consistent with edema. Duodenal biopsies showed focal mucosal erosion and a mononuclear cell infiltrate in the lamina propria consistent with LCH ( Figure 2A). The cells were positive by immunostaining for CD1a, supporting a diagnosis of LCH ( Figure 2B). Colonic biopsies also contained a mononuclear cell infiltrate and CD1a positive staining macrophages ( Figure 2C and D).Chemotherapy was initiated using the LCH-III protocol, which included vinblastine and prednisone. The total duration of the therapy was for 12 months. Vinblastine was given intravenously weekly for 12 weeks and then every 3 weeks for a total of 52 weeks with very few delays and without any major complications. Prednisone was given daily for 6 weeks and then weekly 3-day pulses orally for an additional 10 weeks. Thereafter, Velban was given every 3 weeks with 5 days of ...